Skip to content
Biotechnology, Government VIC

MEDIA OPP: Launch of Bio Innovation Hub opens scope for new disease treatments

La Trobe University < 1 min read

What:

Victorian Government Minister Colin Brooks, representing the Minister for Training and Skills Gayle Tierney, and La Trobe University Vice-Chancellor Professor Theo Farrell, will Launch the new $8 million state-of-the-art Bio Innovation Hub at La Trobe's Melbourne campus in Bundoora.

The purpose-built facility will support the development of world-leading biotechnology and agri-technology businesses. It includes PC2 “wet” laboratories – joining just a handful of the sought-after labs in the state – and world-class equipment to help businesses commercialise their research discoveries. 

 

VivaZome CEO and Managing Director Xenia Sango will outline the development of a new treatment that could potentially reverse or stop progression of traumatic brain injury, using the world-class facilities at the Hub.

The event also includes the official opening of the Jenny Graves Building, named in honour of eminent La Trobe Professor Jenny Graves AC.

 

When:

Friday, 12 July

Building launch 10am

Bio Innovation Hub launch 10.30am

Media to arrive 10 minutes before the launch start times

 

Where:

Level 2, Jenny Graves Building, La Trobe University, Bundoora

See Map for details. Parking is recommended in CP1 or CPV

 

Media enquiries

Robyn Grace I [email protected] I M: 0420826595

Charisse Ede I [email protected] I M: 0404030698

 

More from this category

  • Biotechnology, Medical Health Aged Care
  • 10/04/2026
  • 11:12
Aravax

Aravax Strengthens Board with Appointments of Carsten Hellmann and Andrew Oxtoby

Aravax, a clinical-stage biotechnology company developing next-generation, disease-modifyingimmunotherapies for food allergy, today announces two additions to its Board of Directors, former CEO of ALK-Abello A/S, Carsten Hellmann and former Chief Commercial Officer of Aimmune Therapeutics, Andrew Oxtoby. Collectively, Carsten and Andrew bring to Aravax exceptionally deep experience from the pharmaceutical industry and, specifically, the allergy therapeutics field. Andrew has deep pharmaceutical industry expertise spanning development, product launch, fundraising and exits from working with large and small companies in the U.S. and Europe. As Chief Commercial Officer he built the global commercial organisation for the approval and launch in the US…

  • Biotechnology, Business Company News
  • 10/04/2026
  • 08:00
Cartherics Pty Ltd

Cartherics and Catalent Expand Commercial License Agreement

Melbourne, Australia, and Tampa, FL –Cartherics Pty Ltd, a biotechnology company developing off‑the‑shelf immune cell therapies for high‑impact women’s diseases, including ovarian cancer and endometriosis, and Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, today announced an enhanced partnership. The companies have signed an amended commercial license agreement enabling the use of a Catalent cGMP‑compliant induced pluripotent stem cells (iPSC) line for the manufacture and commercialization of Cartherics’ iPSC-derived Chimeric Antigen Receptor Natural Killer (CAR-NK) cell therapies. The agreement supports Cartherics’ mission to develop immune cell therapy productsfor the treatment of cancer…

  • Biotechnology, Environment
  • 09/04/2026
  • 13:00
Ecopha Biotech

Ecopha Biotech Signals Global Expansion with Australia-India Pongamia Bioeconomy Strategy

Key Facts: Ecopha Biotech announces strategic Australia-India partnership to commercialise their ecopha.bio technology™ for Pongamia-based bioeconomy Technology converts Pongamia oil into sustainable aviation fuel…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.